CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
Abstract Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.222 |